Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird Sells 67,687 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $29.35, for a total value of $1,986,613.45. Following the sale, the chief operating officer now owns 706,872 shares in the company, valued at approximately $20,746,693.20. The trade was a 8.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Melissa Baird also recently made the following trade(s):

• On Tuesday, December 10th, Melissa Baird sold 85,561 shares of Hims & Hers Health stock. The shares were sold at an average price of $31.01, for a total transaction of $2,653,246.61.
• On Monday, November 18th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The stock was sold at an average price of $21.04, for a total transaction of $1,236,100.00.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $30.90 on Friday. The business’s 50-day simple moving average is $27.98 and its 200-day simple moving average is $22.09. Hims & Hers Health, Inc. has a 52 week low of $8.51 and a 52 week high of $35.02. The firm has a market cap of $6.75 billion, a price-to-earnings ratio of 70.22 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same quarter last year, the firm posted ($0.04) earnings per share. The company’s quarterly revenue was up 77.1% compared to the same quarter last year. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on HIMS shares. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Morgan Stanley initiated coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price on the stock. Piper Sandler raised their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Monday, January 6th. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Finally, Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their target price for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus target price of $25.13.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently bought and sold shares of the company. Quest Partners LLC lifted its position in shares of Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares during the last quarter. Stonekeep Investments LLC lifted its stake in shares of Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after buying an additional 882 shares during the period. CWM LLC grew its position in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares in the last quarter. Cadent Capital Advisors LLC increased its stake in Hims & Hers Health by 1.5% during the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock valued at $1,745,000 after acquiring an additional 1,060 shares during the period. Finally, Raleigh Capital Management Inc. lifted its position in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares during the period. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.